drugset / Trial / NCT03246074
Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian Cancer
Phase 1
Completed
35 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) · collabRigel Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research is being done to test the safety of the combination of the study drugs fostamatinib and paclitaxel. This study tests different doses of the drugs to see which doses are safest in people with ovarian cancer when given together.
Timeline
- Start
- 2018-04-03
- Primary completion
- 2022-08-09
- Completion
- 2023-04-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fostamatinib | Small molecule | 100 mg | Oral |
| Subject | Fostamatinib | Small molecule | 150 mg | Oral |
| Subject | Fostamatinib | Small molecule | 200 mg | Oral |
| Background | Paclitaxel | Small molecule | 60 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 80 mg/m2 | — |